IDEX Corporation — 2012 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2012. This is an annual filing; fourth-quarter figures are identified where relevant. IDEX sells engineered pumps, flow meters, fluidics, optical and other specialized products through three segments: Fluid & Metering Technologies (FMT), Health & Science Technologies (HST), and Fire & Safety/Diversified Products (FSDP). Approximately 51% of 2012 sales were outside the United States.
Financial performance
| Metric | 2012 | 2011 | Change / context |
|---|---|---|---|
| Net sales | $1,954.3 million | $1,838.5 million | Up 6%; organic sales up 3%, acquisitions contributed 5%, and foreign currency translation reduced sales 2% |
| Gross profit / margin | $803.7 million / 41.1% | $738.7 million / 40.2% | Margin improved 0.9 percentage points |
| Operating income / margin | $128.2 million / 6.6% | $304.7 million / 16.6% | Decline principally reflected $198.5 million in impairment charges and higher restructuring expense |
| Net income | $37.6 million | $193.9 million | Down 81% |
| Diluted EPS | $0.45 | $2.32 | Down 81% |
| Operating cash flow | $326.2 million | $217.2 million | Up $108.9 million; capital expenditures were $35.5 million |
- Segment results: FMT sales were $833.3 million and operating income was $146.7 million (17.6% margin), versus $831.3 million and $164.8 million in 2011. HST sales rose 14% to $695.2 million, but the segment reported an operating loss of $62.8 million, including $170.8 million of impairment charges. FSDP sales rose 9% to $437.1 million; operating income increased to $96.1 million and margin to 22.0%.
- Liquidity: Cash and cash equivalents were $318.9 million; working capital was $590.4 million and the current ratio was 3.0. Cash flow from operations exceeded capital expenditures.
- Debt: Total borrowings were $786.6 million, down from $808.8 million. The company had $21.0 million drawn on its $700 million revolving facility and approximately $672.5 million of available capacity. Covenant leverage was 1.92x against a 3.25x maximum; interest coverage was 10.05x against a 3.0x minimum. Interest expense rose to $42.3 million from $29.3 million.
- Other: The effective tax rate was 56.3%, largely because of the impairment charge; dividends declared were $0.80 per share. IDEX repurchased 2.2 million shares for $89.6 million during 2012.
Material changes and unusual items
- The fourth quarter included a $198.5 million non-cash impairment charge: $149.8 million of IOP goodwill, $20.7 million of WST goodwill, $21.0 million of CVI Melles Griot trade-name value, and $7.0 million of WST long-lived assets. Management attributed the charges to softness in optics and photonics markets and municipal water markets, as well as a reporting-unit reorganization.
- Restructuring expense increased to $32.5 million from $12.3 million. It included facility closures, employee reductions affecting 491 employees, and termination of a defined-benefit pension plan. The 2011 restructuring initiative was completed by year-end 2012; management said no further restructuring was then planned.
- 2012 acquisitions included Precision Photonics, ERC, and Matcon. Acquisitions contributed to reported sales growth, while HST organic sales declined 1%; FMT organic sales increased 2% and FSDP organic sales increased 11%.
- Reporting units within FMT were reorganized in the fourth quarter, including creation of Diaphragm & Dosing Pump Technology and Water Services & Technology.
Outlook, risks, and contingencies
- Management forecast 2013 fully diluted EPS of $2.85–$2.95. It described North America as strong, Asian markets as improving, and Europe as stabilizing. The filing gives no quantified 2013 sales or organic-growth guidance.
- Key risks include economic weakness in the company’s end markets, international exposure and currency movements, competitive and pricing pressures, dependence on product development, acquisition execution and integration, and raw-material availability and costs. Goodwill and intangible assets remained substantial at year-end, making future results sensitive to impairment assumptions and performance.
- Asbestos-related lawsuits were pending. The company reported that most resolved claims had been dismissed without payment or settled for insignificant amounts, and that insurance had historically covered most settlement and legal costs, subject to deductibles. Management had not recorded a provision beyond ordinary-course insurance deductibles and did not then expect a material adverse effect. Other ordinary-course proceedings were not expected to be material.
- Management stated that existing cash and expected operating cash flow would cover operating needs, planned capital expenditures, debt interest, benefit-plan funding, authorized repurchases, and dividends for the next 12 months. About $201.9 million of cash was held outside the United States and treated as permanently invested.
- The independent auditor issued unqualified opinions on the financial statements and internal control over financial reporting. The internal-control audit excluded the three businesses acquired in 2012.
Important facts for investors to verify
- Whether underlying organic growth, particularly in HST optics and scientific instrumentation and FMT municipal water markets, supports the 2013 EPS forecast.
- The assumptions and sensitivity behind the IOP and WST impairment tests, and whether further impairment indicators emerge.
- Cash conversion, restructuring cash costs, and the extent to which 2012 operating cash flow benefited from working-capital changes and non-cash adjustments.
- Debt maturities, refinancing needs, covenant headroom, and the company’s capacity to fund acquisitions alongside dividends and share repurchases.
- Whether acquisition integration and the acquired businesses’ performance meet expectations, including Matcon contingent consideration and the control environment at acquired entities.
- Potential changes in asbestos insurance coverage, litigation exposure, pension funding requirements, and taxes associated with foreign earnings or repatriation.